Eur Heart J:长期用抗生素的中老年女士更易发生心血管病

2019-04-27 朱柳媛 中国循环杂志

来自美国护士健康研究(Nurses’ Health Study)的一项最新分析结果表明,长期应用抗生素的女士发生心脏病和中风的风险明显增加。

来自美国护士健康研究(Nurses’ Health Study)的一项最新分析结果表明,长期应用抗生素的女士发生心脏病和中风的风险明显增加。

其中,应用抗生素超过2个月的60岁以上老年女士发生血管病的风险最高。当然,在40~59岁的中年女士中,抗生素应用的时间越长,血管病风险也越高。

但是,在20~39岁的女士中,应用抗生素并没有导致心血管病风险升高。

研究者指出,长期应用抗生素会破坏肠道微生态平衡,导致有益细菌减少,而对身体有害的病毒、细菌和其他微生物增加,从而导致心血管病发生风险增加。

这项最新分析纳入36 429例女性受试者,根据抗生素应用的时间长短分为四组:从未应用抗生素以及应用抗生素<15天、15天~2个月、≥2个月。平均随访7.6年期间,1056例受试者发生心血管病。

校正年龄、种族、性别、饮食和生活方式、应用抗生素的原因、超重或肥胖、其他疾病和用药等因素后,研究人员发现,应用抗生素≥2个月的老年女士发生心血管病的风险比从不用抗生素者增加32%,该组的中年女士中心血管病风险增加28%。

研究者认为,随着年龄增长,受试者可能需要应用更多的抗生素,有时需要应用较长时间,导致老年女士中出现累积效应,因此心血管病发生风险更高。

在该研究中,受试者应用抗生素的最常见原因是呼吸道感染、尿路感染和牙科问题。

研究者建议,只有在绝对必需应用抗生素的时候才用,而且为了避免风险累积效应,应用时间越短越好。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1644751, encodeId=02181644e51b3, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Feb 20 10:44:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923791, encodeId=a8451923e9192, content=<a href='/topic/show?id=56a522389f9' target=_blank style='color:#2F92EE;'>#中老年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22389, encryptionId=56a522389f9, topicName=中老年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Tue Jan 28 19:44:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357183, encodeId=a70c135e183aa, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 29 00:44:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563093, encodeId=fd6a15630932a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Apr 29 00:44:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365358, encodeId=88e936535801, content=学习推荐分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=650f104372, createdName=gcwu82, createdTime=Sat Apr 27 11:36:13 CST 2019, time=2019-04-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1644751, encodeId=02181644e51b3, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Feb 20 10:44:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923791, encodeId=a8451923e9192, content=<a href='/topic/show?id=56a522389f9' target=_blank style='color:#2F92EE;'>#中老年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22389, encryptionId=56a522389f9, topicName=中老年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Tue Jan 28 19:44:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357183, encodeId=a70c135e183aa, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 29 00:44:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563093, encodeId=fd6a15630932a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Apr 29 00:44:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365358, encodeId=88e936535801, content=学习推荐分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=650f104372, createdName=gcwu82, createdTime=Sat Apr 27 11:36:13 CST 2019, time=2019-04-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1644751, encodeId=02181644e51b3, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Feb 20 10:44:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923791, encodeId=a8451923e9192, content=<a href='/topic/show?id=56a522389f9' target=_blank style='color:#2F92EE;'>#中老年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22389, encryptionId=56a522389f9, topicName=中老年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Tue Jan 28 19:44:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357183, encodeId=a70c135e183aa, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 29 00:44:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563093, encodeId=fd6a15630932a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Apr 29 00:44:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365358, encodeId=88e936535801, content=学习推荐分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=650f104372, createdName=gcwu82, createdTime=Sat Apr 27 11:36:13 CST 2019, time=2019-04-27, status=1, ipAttribution=)]
    2019-04-29 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1644751, encodeId=02181644e51b3, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Feb 20 10:44:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923791, encodeId=a8451923e9192, content=<a href='/topic/show?id=56a522389f9' target=_blank style='color:#2F92EE;'>#中老年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22389, encryptionId=56a522389f9, topicName=中老年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Tue Jan 28 19:44:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357183, encodeId=a70c135e183aa, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 29 00:44:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563093, encodeId=fd6a15630932a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Apr 29 00:44:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365358, encodeId=88e936535801, content=学习推荐分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=650f104372, createdName=gcwu82, createdTime=Sat Apr 27 11:36:13 CST 2019, time=2019-04-27, status=1, ipAttribution=)]
    2019-04-29 hb2008ye
  5. [GetPortalCommentsPageByObjectIdResponse(id=1644751, encodeId=02181644e51b3, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Feb 20 10:44:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923791, encodeId=a8451923e9192, content=<a href='/topic/show?id=56a522389f9' target=_blank style='color:#2F92EE;'>#中老年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22389, encryptionId=56a522389f9, topicName=中老年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Tue Jan 28 19:44:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357183, encodeId=a70c135e183aa, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 29 00:44:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563093, encodeId=fd6a15630932a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Apr 29 00:44:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365358, encodeId=88e936535801, content=学习推荐分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=650f104372, createdName=gcwu82, createdTime=Sat Apr 27 11:36:13 CST 2019, time=2019-04-27, status=1, ipAttribution=)]
    2019-04-27 gcwu82

    学习推荐分享

    0

相关资讯

抗生素治疗阿兹海默病?这家公司递交上市申请了

总部位于美国加州旧金山市南部的Cortexyme近日递交了8600万美元的IPO申请,这家私人控股的临床阶段公司,专注于阿兹海默病和其他神经退行性疾病治疗的药物研发。值得一提的是,2018年6月,该公司获得了由辉瑞(Pfizer)、红杉资本、武田风险投资等知名机构投资的7600万美元B轮融资。 阿兹海默病是全球影响最广的神经退行性疾病。随着世界人口老龄化,阿兹海默病的发病率迅速增

Molecular Microbiology:揭示喹诺酮抗性蛋白介导的细菌耐药机制

细菌抗生素耐药性是预防传染病的重大威胁,通常是由质粒转移或基因突变引起的。当细菌暴露于抗生素环境中会通过提高细菌的突变率筛选出适应抗生素环境的基因突变,结果导致临床环境中耐药菌株的出现。质粒驱动抗生素抗性基因的水平转移,引发细菌耐药性的产生。此外,质粒和细菌染色体之间的相互作用会影响抗生素抗性的传播,了解这些过程背后的机制将提供细菌如何适应抗生素环境的见解,并有助于优化抗菌策略。

抗生素的使用策略 你入坑了么?

误区一、抗生素耐药=治疗无效抗生素的耐药性越来越普遍,临床上的耐药性菌甚至是多重耐药菌越来越多见。抗生素耐药是指抗生素的常用剂量下血药浓度低于细菌的最小有效抑菌浓度(MIC),那么如果根据患者病情具体情况,采取增加用药剂量、联合用药或者抗菌药物在感染部位的组织浓度高等措施,抗感染治疗仍可有效。治疗无效也不等于抗生素耐药。抗生素抗感染治疗需要一定的时间,治疗是否有效并不以某一症状是否消失为标准。临床

Communications Biologyvolume:科学家发现基于砷的新型广谱抗生素

抗生素耐药性被认为是这个时代最大的公共健康威胁之一。我们迫切地需要新型抗生素来对抗日益增长的全世界范围内的耐药性细菌。近日,一个国际研究团队发现了一种含有砷的新型广谱抗生素。这项近日已发表在《Nature》子刊《Communication Biology》上。

Ann Rheum Dis:细菌性关节炎外科引流术后2周与4周抗生素治疗的比较

对化脓性关节炎进行初步手术灌洗后,至少对于手部和腕关节炎,2周的靶向抗生素治疗在治愈率、不良事件或后遗症方面并不劣于4周,并使得住院时间明显缩短。

看完这篇文章,还敢滥用抗生素?!

动不动让医生开抗生素,“超级细菌”离我们不远了!